The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the
rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS …

While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent
nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir …

Remdesivir is an antiviral approved for COVID-19 treatment, but its wider use is limited by
intravenous delivery. An orally bioavailable remdesivir analog may boost therapeutic benefit …

The outbreak of coronavirus disease 2019 (COVID-19) has resulted in a global pandemic
due to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-
2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the …

The ongoing SARS‐CoV‐2 pandemic stresses the need for effective antiviral drugs that can
quickly be applied in order to reduce morbidity, mortality, and ideally viral transmission. By …

Remdesivir 1 is an phosphoramidate prodrug that releases the monophosphate of
nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP …

Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small
molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports …

Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …